published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID 19 all comers - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsGunst JD, 2021 0.99 [0.29; 3.42] NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03] Tang X, 2020 0.98 [0.93; 1.02] University of Minnesota, 2020 1.29 [0.51; 3.26] 0.96[0.89; 1.05]Gunst JD, 2021, NIH NIAID ACTT-1, 2020, Tang X, 2020, University of Minnesota, 202043%1,558moderatenot evaluable death or transfer to ICUdetailed resultsBACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88] Gunst JD, 2021 0.55 [0.26; 1.17] 0.75[0.43; 1.31]BACC Bay Tocilizumab Trial, 2020, Gunst JD, 2021218%447lownot evaluable deathsdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62] Gunst JD, 2021 0.70 [0.20; 2.49] NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84] Tang X, 2020 0.98 [0.93; 1.02] University of Minnesota, 2020 0.68 [0.11; 4.16] 0.81[0.56; 1.18]BACC Bay Tocilizumab Trial, 2020, Gunst JD, 2021, NIH NIAID ACTT-1, 2020, Tang X, 2020, University of Minnesota, 2020550%1,803moderatenot evaluable deaths (time to event analysis only)detailed resultsGunst JD, 2021 0.70 [0.20; 2.49] NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84] 0.56[0.38; 0.84]Gunst JD, 2021, NIH NIAID ACTT-1, 202020%1,270moderatenot evaluable clinical deteriorationdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09] Tang X, 2020 1.00 [0.13; 7.45] 1.10[0.60; 2.01]BACC Bay Tocilizumab Trial, 2020, Tang X, 202020%328lownot evaluable clinical improvementdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41] Gunst JD, 2021 1.14 [0.83; 1.57] NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49] Tang X, 2020 1.04 [0.67; 1.62] 1.21[1.08; 1.36]BACC Bay Tocilizumab Trial, 2020, Gunst JD, 2021, NIH NIAID ACTT-1, 2020, Tang X, 202040%1,598moderatenot evaluable clinical improvement (14-day)detailed resultsTang X, 2020 1.33 [0.57; 3.11] 1.33[0.57; 3.11]Tang X, 202010%86NAnot evaluable clinical improvement (28-day)detailed resultsNIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76] 1.35[1.03; 1.76]NIH NIAID ACTT-1, 202010%1,062NAnot evaluable clinical improvement (time to event analysis only)detailed resultsGunst JD, 2021 1.14 [0.83; 1.57] NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49] sarimulab phase 2 low dose, 0 0.96 [0.53; 1.73] Tang X, 2020 1.04 [0.67; 1.62] 1.23[1.09; 1.39]Gunst JD, 2021, NIH NIAID ACTT-1, 2020, sarimulab phase 2 low dose, 0, Tang X, 202040%1,603moderatenot evaluable death or ventilationdetailed resultsBACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81] 0.83[0.38; 1.81]BACC Bay Tocilizumab Trial, 202010%242NAnot evaluable hospital dischargedetailed resultsUniversity of Minnesota, 2020 0.64 [0.37; 1.11] 0.64[0.37; 1.11]University of Minnesota, 202010%205NAnot evaluable hospitalizationdetailed resultsEPIC-SR, 0 0.29 [0.08; 1.07] University of Minnesota, 2020 1.63 [0.94; 2.85] 0.77[0.14; 4.08]EPIC-SR, 0, University of Minnesota, 2020282%1,059lownot evaluable mechanical ventilationdetailed resultsGunst JD, 2021 2.27 [0.62; 8.26] University of Minnesota, 2020 1.34 [0.66; 2.73] 1.52[0.82; 2.83]Gunst JD, 2021, University of Minnesota, 202020%408moderatenot evaluable mechanical ventilation (time to event analysis only)detailed resultsGunst JD, 2021 0.69 [0.14; 3.42] 0.69[0.14; 3.42]Gunst JD, 202110%208NAnot evaluable viral clearance detailed resultsTang X, 2020 1.78 [1.06; 3.00] 1.78[1.06; 3.00]Tang X, 202010%86NAnot evaluable viral clearance (time to event analysis only)detailed resultsTang X, 2020 1.78 [1.06; 3.00] 1.78[1.06; 3.00]Tang X, 202010%86NAnot evaluable ICU admissiondetailed resultsGunst JD, 2021 0.80 [0.34; 1.90] Tang X, 2020 1.00 [0.13; 7.45] 0.83[0.37; 1.83]Gunst JD, 2021, Tang X, 202020%291moderatenot evaluable recoverydetailed resultsGunst JD, 2021 1.18 [0.87; 1.61] 1.18[0.87; 1.61]Gunst JD, 202110%208NAnot evaluable serious adverse eventsdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53] Gunst JD, 2021 1.84 [0.79; 4.30] NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96] 1.05[0.59; 1.86]BACC Bay Tocilizumab Trial, 2020, Gunst JD, 2021, NIH NIAID ACTT-1, 2020362%1,510moderatenot evaluable adverse eventsdetailed resultsGunst JD, 2021 0.80 [0.43; 1.51] 0.80[0.43; 1.51]Gunst JD, 202110%205NAnot evaluable deep vein thrombosisdetailed resultsNIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81] 0.64[0.23; 1.81]NIH NIAID ACTT-1, 202010%1,063NAnot evaluable elevated liver enzymesdetailed resultsNIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18] 0.67[0.38; 1.18]NIH NIAID ACTT-1, 202010%1,063NAnot evaluable hyperbilirubinemiadetailed resultsNIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34] 0.84[0.30; 2.34]NIH NIAID ACTT-1, 202010%1,063NAnot evaluable pulmonary embolismdetailed resultsNIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80] 0.96[0.19; 4.80]NIH NIAID ACTT-1, 202010%1,063NAnot evaluable renal impairmentdetailed resultsNIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61] 1.02[0.64; 1.61]NIH NIAID ACTT-1, 202010%1,063NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-19 21:04 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 94 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290